Company profile
RHYTHM PHARMACEUTICALS, INC.
NASDAQ:RYTMBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SETMELANOTIDE ACETATE | approved | — | 0 | — |
| SETMELANOTIDE | phase1 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (25)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07156578 | phase2 | enrolling_by_invitation | 2025-11-10 | 2028-04-15 | Rhythm Pharmaceuticals, Inc. | A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) |
| NCT04348175 | phase1 | completed | 2020-07-09 | 2021-04-17 | Rhythm Pharmaceuticals, Inc. | A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment |
| NCT06239116 | phase1_2 | recruiting | 2024-03-05 | 2027-11-01 | Rhythm Pharmaceuticals, Inc. | A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment |
| NCT06772597 | phase2 | active_not_recruiting | 2025-03-04 | 2026-10-31 | Rhythm Pharmaceuticals, Inc. | A Study of Setmelanotide in Patients With Prader-Willi Syndrome |
| NCT06046443 | phase2 | completed | 2024-07-11 | 2026-02-09 | Rhythm Pharmaceuticals, Inc. | A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 213793 | NDA | RHYTHM PHARMACEUTICALS INC | ||||
Loading… | ||||||